---
title: "Zenocutuzumab treatment shows continued benefit in NRG1+ NSCLC patients beyond progression: eNRGy trial results."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276445902.md"
description: "Partner Therapeutics, Inc. announced on February 20, 2026, the results of a supplementary examination of the eNRGy trial, focusing on zenocutuzumab treatment for advanced NRG1+ non-small cell lung cancer (NSCLC) patients. The study demonstrated continued benefits of zenocutuzumab even after disease progression, indicating its potential effectiveness beyond standard treatment endpoints. The trial involved a significant number of participants, emphasizing the innovative treatment's impact on this specific cancer type."
datetime: "2026-02-20T13:03:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276445902.md)
  - [en](https://longbridge.com/en/news/276445902.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276445902.md)
generator: "portal-rs"
---

# Zenocutuzumab treatment shows continued benefit in NRG1+ NSCLC patients beyond progression: eNRGy trial results.

In Lexington, Massachusetts on February 20, 2026, Partner Therapeutics, Inc. (PTx) shared results of a supplementary examination of the eNRGy trial (NCT02912949) focusing on extending treatment with zenocutuzumab in patients with advanced neuregulin 1 fusion-positive (NRG1+) non-small cell cancer. The study delved into the efficacy of this approach in cases where the disease continued to progress. This analysis sheds light on the potential benefits of zenocutuzumab beyond the standard treatment endpoints. The trial encompassed a significant number of participants, highlighting the potential impact of this innovative treatment approach on patients with this specific type of cancer.

### Related Stocks

- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [MRUS.US](https://longbridge.com/en/quote/MRUS.US.md)

## Related News & Research

- [Sacituzumab Govitecan Plus Pembrolizumab Does Not Meet Primary Endpoints in First-Line PD-L1-High Metastatic NSCLC](https://longbridge.com/en/news/298830378.md)
- [FDA grants priority review to Genentech’s Enspryng for MOGAD](https://longbridge.com/en/news/298539804.md)
- [“We’re not doing 30 bets a year”: Vijay Pande on betting small after running $4 billion at a16z](https://longbridge.com/en/news/297407072.md)
- [Grupa Azoty announces extraordinary shareholder meeting](https://longbridge.com/en/news/297635728.md)
- [Koala trial doses first patient with novel KMA‑targeting CAR‑T](https://longbridge.com/en/news/298021066.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**